Bookmarks
Investigating Interactions between Mycobacterium Tuberculosis and SARS-CoV-2
Population Size
4,465
People
Years
2020 - 2020
Associated BioSamples
None/not available
Geographic coverage
United Kingdom
England
Lead time
1-2 months
Summary
Documentation
Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. TB remains a significant global health problem. The UK has one of the highest rates of TB in Europe, with almost 5000 new cases notified in 2019. Within the UK, Birmingham and the West Midlands are particular hotspots for TB, with over 300 cases of active disease and approximately 10 times that of new latent infections diagnosed each year.
Birmingham and the West Midlands have experienced particularly high rates of COVID-19 during the pandemic and there is increasing evidence that individuals of Black, Asian and minority ethnicities (BAME) experience the most significant morbidity and highest mortality rates due to COVID-19. These groups also experience the highest burdens of TB, both in the UK and overseas.
Epidemiological data suggests that current and previous tuberculosis (TB) increase the risk of COVID-19 mortality and severe disease. There is also evidence of immunopathogenic overlap between the two infections with in vitro studies finding that SARS-CoV-2 infection is increased in human macrophages cultured in the inflammatory milieu of TB-infected macrophages.
This dataset would enable a deeper analysis of demography and clinical outcomes associated with COVID-19 in patients with concurrent TB.
PIONEER geography: the West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix.
EHR. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & an expanded 250 ITU bed capacity during COVID. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.
Scope: All hospitalised patients admitted to UHB during the COVID-19 pandemic, curated to focus on Mycobacterium tuberculosis and SARS-CoV-2. Longitudinal & individually linked, so that the preceding & subsequent health journey can be mapped & healthcare utilisation prior to & after admission understood. The dataset includes highly granular patient demographics & co-morbidities taken from ICD-10 & SNOMED-CT codes. Serial, structured data pertaining to acute care process (A&E, triage, IP, ITU admissions), presenting complaint, DNAR teal, all physiology readings (AVPU scale, Covid CFS, blood pressure, respiratory rate, oxygen saturations and others), all blood results, imaging reports, all prescribed & administered treatments, all outcomes.
Available supplementary data: Matched controls; ambulance, OMOP data, synthetic data.
Available supplementary support: Analytics, Model build, validation & refinement; A.I.; Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.
Dataset type
Dataset sub-type
Dataset population size
Keywords
Observations
Observed Node | Disambiguating Description | Measured Value | Measured Property | Observation Date |
---|---|---|---|---|
Persons | 4,465 spells with COVID and 55 patients with TB and COVID | 4465 | Count | 31 Jul 2022 |
Provenance
Purpose of dataset collection
Source of data extraction
Collection source setting
Patient pathway description
Image contrast
Biological sample availability
Structural Metadata
Details
Publishing frequency
Version
Modified
08/10/2024
Distribution release date
05/10/2023
Citation Requirements
Coverage
Start date
01/03/2020
End date
31/10/2020
Time lag
Geographic coverage
Minimum age range
Maximum age range
Follow-up
Accessibility
Language
Alignment with standardised data models
Controlled vocabulary
Format
Data Access Request
Dataset pipeline status
Time to dataset access
Access request cost
Access method category
Access service description
Trusted Research Environments (TRE) are built using Microsoft Azure services and hosted in the UK to provide research teams a safe, secure and agile environment which allows users to quickly analyse, interpret and form an enriched view of primary care information through a range of integrated datasets.
Health data collated from multiple sources is ingested into a secure data lake which will then allow subsets of data to be made available to research teams on approval of a data request. Once approved a customer specific TRE is made available with a standard set of leading analytical tools from Microsoft including Azure Databricks, Azure Machine Learning, Azure SQL and Azure Synapse (for large-scale data warehouses). Specific tools can be provided at an additional cost over the standard platform data access charge and the PIONEER team will work with you to determine your exact needs.
Access to the TRE is managed using the latest virtual desktop technology to provide a safe and secure end-user experience. By utilising leading edge design PIONEER are able to create TREs rapidly to enable us to service any customer requirement.
Jurisdiction
Data use limitation
Data use requirements
Data Controller